ADCs work by exploiting the unique expression of specific antigens on the surface of cancer cells. After administration, the monoclonal antibody component of the ADC binds to its target antigen, leading to internalization of the ADC into the cancer cell. Once inside, the linker is cleaved, releasing the cytotoxic drug, which then exerts its toxic effect, leading to cell death.
